Reprogramming Tumor Antigenicity & Enhancing Immunotherapy Responsiveness with an Antibody-Targeted RNAi Platform

• Showcasing early preclinical evidence of tumor-selective siRNA activity with minimized off-target effects through aptamer-based targeting
• Introducing the Antibody-Oligonucleotide Conjugate (AOC) platform and proof-ofconcept studies validating precision tumor delivery
• Presenting data from lead candidate selection and in-depth characterization to demonstrate potency and durability
• Exploring future opportunities to integrate Sebastian BioPharma’s RNAi platforms with checkpoint inhibitors and precision medicine strategies to expand patient benefit

Speakers:

Greta Garrido

Chief Executive Officer & Co-Founder

Sebastian BioPharma